Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002834 | 0.80 | HSD17B10 (0.40) | MAPTNOTUMIKBKBCHUKMAP4K4 | |
| SCHEMBL2674160 | 0.80 | MAPT (0.34) | MAPTMAP2K1 | |
| SCHEMBL2673270 | 0.80 | CYP2A6 (0.40) | MAPTPRKAA1BRD4CYP2A6MEN1 | |
| SCHEMBL20227365 | 0.80 | MAPT (0.34) | MAPTALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL4001882 | 0.76 | KIF11 (0.38) | NOTUMBACE1 | |
| SCHEMBL25849810 | 0.75 | C1R (0.35) | MAPTNOTUMALDH1A1RAB9ANPC1 | |
| SCHEMBL10232401 | 0.74 | MAPT (0.41) | MAPTNOTUMDYRK1ADYRK1BALDH1A1 | |
| SCHEMBL10921529 | 0.73 | FBP1 (0.49) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5534778 | 0.72 | ALDH1A1 (0.47) | MAPTPARP1ALDH1A1RAB9ANPC1 | |
| SCHEMBL3976914 | 0.71 | MAPT (0.63) | MAPTNOTUMPARP1JAK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1829697-A | Aryl-heteroaromatic products, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2006-09-06 | — | — | CN | claimed |
| US-10253033-B2 | De novo synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180072746-A1 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | UNIV NORTH CAROLINA STATE (US) | 2018-03-15 | — | — | US | disclosed |
| US-9822123-B2 | De novo synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2017-11-21 | — | — | US | disclosed |
| CN-105026399-B | As the pyrrolo-triazine class compound of potassium channel inhibitors | 百时美施贵宝公司 | 2017-06-23 | — | — | CN | disclosed |
| CN-103333171-B | Synthetic method of pyrrole [1,2-a ] quinoxaline derivative | NANJING TECH UNIVERSITY (CN) | 2015-10-28 | — | — | CN | disclosed |
| US-20140371286-A1 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| US-8664260-B2 | De novo synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-03-04 | — | — | US | disclosed |
| CN-103342705-A | Method for synthesizing pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-09 | — | — | CN | disclosed |
| CN-103333171-A | Synthetic method of pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-02 | — | — | CN | disclosed |
| EP-1848778-A2 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | North Carolina State University (US) | 2007-10-31 | — | — | EP | disclosed |
| CN-1829697-A | Aryl-heteroaromatic products, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2006-09-06 | — | — | CN | disclosed |
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-31 | — | — | US | disclosed |
| WO-2006089122-A2 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | NORTH CAROLINA STATE UNIVERSITY (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1487887-A2 | POLYCYCLIC, FUSED HETERORING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | Dow Global Technologies Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078480-A2 | POLYCYCLIC, FUSED HETERORING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1153047-A1 | METALLOCENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CATALYTIC SYSTEMS FOR THE POLYMERIZATION OF OLEFINS | Basell Technology Company B.V. (NL) | 2001-11-14 | — | — | EP | disclosed |
| WO-2001044318-A1 | METALLOCENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CATALYTIC SYSTEMS FOR THE POLYMERIZATION OF OLEFINS | BASELL TECHNOLOGY COMPANY B.V. (NL) | 2001-06-21 | — | — | WO | disclosed |
| EP-0358047-A2 | Method of controlling phytopathogenic fungi | AMERICAN CYANAMID COMPANY (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0347488-A1 | Arylpyrrole insecticidal acaricidal and nematicidal agents and method for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253033-B2 | De novo synthesis of bacteriochlorins | BCL6, ALDH1A2, ALAD | MAPT 2853/4885NOTUM 295/4885PARP1 778/4885 |
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | PCNA, SCD, BCL6 | MAPT 2061/4885NOTUM 1308/4885PARP1 78/4885 |
| US-20140371286-A1 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | BCL6, ALDH1A2, ALAD | MAPT 2853/4885NOTUM 295/4885PARP1 778/4885 |
| US-20180072746-A1 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | BCL6, ALDH1A2, ALAD | MAPT 2853/4885NOTUM 295/4885PARP1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.